Fennec Pharmaceuticals Granted FDA Approval For PEDMARK
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212937
Capital One Initiates Coverage On Fennec Pharmaceuticals with Overweight Rating, Announces Price Target of $11
Capital One analyst Naureen Quibria initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $11.
Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Fennec Pharma to Receive Investment from Petrichor Healthcare Management, $5M of Convertible Debt to be Purchased Upon Closing
An additional $20 million to be funded upon the potential U.S. Food and Drug Administration (FDA) approval of PEDMARKTM by September 30, 2022 and satisfaction of other closing conditions. Fennec upon
Fennec Pharmaceuticals Resubmits New Drug Application To FDA For Pedmark
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also rose, gaining 1.55% to 4,665.67.
Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11.
33 Stocks Moving In Monday’s Mid-Day Session
Gainers
Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB).